Evidence method
Level · gp.fundamentals.debt_to_revenue
51.81% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Dec 31, 2024
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001023024-25-000015General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.64% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
10.42% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
26.20% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
22.26% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.operating_margin
0.10% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
7.26% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
4.78% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 215.78%
- Current
- 51.81%
- Delta
- -163.97%
- Previous
- 3.24%
- Current
- 2.64%
- Delta
- -0.60%
- Previous
- 8.41%
- Current
- 10.42%
- Delta
- 2.01%
- Previous
- 12.52%
- Current
- 26.20%
- Delta
- 13.68%
- Previous
- 99.80%
- Current
- 22.26%
- Delta
- -77.54%
- Previous
- -13.83%
- Current
- 0.10%
- Delta
- 13.93%
- Previous
- 6.83%
- Current
- 7.26%
- Delta
- 0.43%
- Previous
- 5.05%
- Current
- 4.78%
- Delta
- -0.27%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_DECREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP PROFITABILITY_INCREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.